Fight Against Cancer Innovation Trust

FACIT's deal flow originates primarily from the Ontario Institute for Cancer Research and affiliated academic and hospital research networks across Ontario. The firm's translational mandate gives it early access to oncology innovations before they become widely known to generalist investors. It also scouting programs and pitch competitions, such as Falcons' Fortunes, to identify emerging academic founders.

FACIT makes direct equity investments in oncology start-ups. It also manages structured programs — the Prospects Fund, Compass Rose, and WeSEED — that provide capital at different stages of company development. These vehicles are direct-investment oriented, not fund-of-funds commitments, though the firm syndicates rounds with external angel and institutional investors.

FACIT was established by the Ontario Institute for Cancer Research to serve as its commercialization and technology-transfer arm. While FACIT operates as an independent venture firm, it works closely with OICR's research pipeline and receives part of its funding through the Government of Ontario via OICR. This relationship ties FACIT's investment strategy to a provincial economic development mandate.

FACIT invests across therapeutics, medical devices, and diagnostics — all focused on oncology. Its portfolio includes companies developing immunotherapies, targeted small molecules, surgical visualization technology, and molecular diagnostics. The unifying thread is an origin in Ontario research and a clear path to addressing unmet cancer patient needs.

Yes. FACIT's mandate explicitly aims to keep skilled teams, intellectual property, and sustainable companies within the province. Its investment terms and governance structures typically require company headquarters and key operations to stay in Ontario, reinforcing its 'Ontario First' capital model and economic development goals.